Robert Towarnicki

Robert Towarnicki has extensive experience in the biotechnology industry. Robert is currently the Founder, President, and CEO of SIRPant Immunotherapeutics, a biotechnology company focused on developing cell therapy for solid tumors. Prior to this role, they were the Managing Partner of New Hope BioConsulting, providing strategic services to investors and businesses in the biotech, pharmaceutical, and medical device sectors. Robert also served as the Managing Partner of Equine Advantage, developing health and performance enhancement products for the equestrian market. Previously, they worked as a Consultant and Acting President at Royer Biomedical, a company specialized in localized therapeutic systems. Robert served as the President of ExSAR Corporation, offering analytical services to pharmaceutical companies. Additionally, they held executive positions at Makefield Therapeutics and Nucleonics, where they developed and commercialized pharmaceutical products based on innovative technologies. Throughout their career, Robert Towarnicki has been actively involved in the biotech industry, serving on the boards of Biotechnology Industry Organization, VectraMed, and Pennsylvania Bio.

Robert Towarnicki earned a Bachelor of Science degree in Biology, specializing in Microbiology, General, from Villanova University in 1973. Robert further pursued their education at Villanova University, where they obtained a Master of Science degree in Biology in 1974.